Q4 2024 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2025-02-14 · accession 0001104659-25-014085
$9.36B
Reported value
95
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45337C102 | INCY | Incyte Corporation | $2.12B | 22.7% | 30,739,466 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $1.76B | 18.8% | 9,531,880 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $786.8M | 8.40% | 42,877,916 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $609.3M | 6.51% | 1,974,590 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $435.9M | 4.66% | 24,424,865 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $347.2M | 3.71% | 7,936,972 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $345.7M | 3.69% | 5,006,863 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $340.6M | 3.64% | 6,084,249 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $241.2M | 2.58% | 5,995,929 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $172.2M | 1.84% | 17,310,490 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $164.4M | 1.76% | 6,155,940 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $152.4M | 1.63% | 10,885,357 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $133.8M | 1.43% | 11,045,336 | Common | SOLE |
| G01767105 | ALKS | Alkermes plc | $120.3M | 1.28% | 4,181,751 | Common | SOLE |
| 457669AB5 | INSM 0.75 06/01/28 | Insmed Incorporated | $92.9M | 0.99% | 42,850,000 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $84.1M | 0.90% | 4,865,819 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $80.7M | 0.86% | 27,525,640 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $76.1M | 0.81% | 3,731,695 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $73.1M | 0.78% | 3,882,125 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $68.8M | 0.74% | 111,904 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $66.3M | 0.71% | 1,576,114 | Common | SOLE |
| G52694109 | KNSA | Kiniksa Pharmaceuticals International, plc | $55.7M | 0.60% | 2,818,323 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $51.7M | 0.55% | 7,275,830 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $51.5M | 0.55% | 1,308,011 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $51.1M | 0.55% | 4,633,838 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $44.7M | 0.48% | 1,515,318 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $44.6M | 0.48% | 3,767,773 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $44.2M | 0.47% | 5,434,399 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $42.3M | 0.45% | 1,707,881 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $39.0M | 0.42% | 993,679 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $35.1M | 0.37% | 2,678,553 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $34.1M | 0.36% | 4,916,095 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $30.5M | 0.33% | 1,097,082 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $30.0M | 0.32% | 19,477,339 | Common | SOLE |
| 462222AF7 | IONS 1.75 06/15/28 | Ionis Pharmaceuticals, Inc. | $29.5M | 0.32% | 30,000,000 | Common | SOLE |
| 384747101 | GRAL | GRAIL, Inc. | $29.1M | 0.31% | 1,630,125 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $27.3M | 0.29% | 1,062,123 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $26.6M | 0.28% | 169,934 | Common | SOLE |
| 137404109 | CADL | Candel Therapeutics, Inc. | $25.9M | 0.28% | 2,981,983 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $25.5M | 0.27% | 331,533 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $25.0M | 0.27% | 4,094,304 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $20.6M | 0.22% | 1,227,178 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $18.9M | 0.20% | 450,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $15.8M | 0.17% | 672,096 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $15.4M | 0.16% | 674,450 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $15.4M | 0.16% | 670,431 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $14.5M | 0.16% | 833,333 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $12.9M | 0.14% | 10,123,824 | Common | SOLE |
| 462222100 | IONS | Ionis Pharmaceuticals, Inc. | $12.5M | 0.13% | 357,915 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $12.3M | 0.13% | 1,562,500 | Common | SOLE |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $11.0M | 0.12% | 1,034,600 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $10.8M | 0.11% | 1,743,725 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc. | $9.8M | 0.10% | 361,565 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $9.5M | 0.10% | 1,691,530 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $8.5M | 0.09% | 2,173,622 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $8.5M | 0.09% | 2,784,792 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $8.3M | 0.09% | 1,201,894 | Common | SOLE |
| 92764N102 | VIR | Vir Biotechnology, Inc. | $8.0M | 0.09% | 1,084,539 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $7.9M | 0.08% | 190,476 | Common | SOLE |
| 04335A105 | ARVN | Arvinas, Inc. | $7.8M | 0.08% | 405,576 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $7.5M | 0.08% | 644,116 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $7.3M | 0.08% | 2,497,526 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $6.9M | 0.07% | 4,004,756 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $6.3M | 0.07% | 247,644 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $5.6M | 0.06% | 1,451,990 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $5.4M | 0.06% | 3,258,402 | Common | SOLE |
| 09075V102 | BNTX | BioNTech SE | $5.1M | 0.05% | 45,031 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $4.9M | 0.05% | 77,050 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $4.8M | 0.05% | 1,160,117 | Common | SOLE |
| 21217B100 | CTNM | Contineum Therapeutics, Inc. | $4.6M | 0.05% | 312,500 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S.A. | $4.5M | 0.05% | 1,461,425 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $4.3M | 0.05% | 952,996 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd. | $4.3M | 0.05% | 344,063 | Common | SOLE |
| 83086J200 | SKYE | Skye Bioscience, Inc. | $4.1M | 0.04% | 1,450,638 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $4.0M | 0.04% | 48,885 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.9M | 0.04% | 2,380,949 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $3.4M | 0.04% | 1,172,175 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics, Inc. | $3.3M | 0.04% | 83,055 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $3.0M | 0.03% | 1,028,466 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $2.8M | 0.03% | 536,832 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $2.6M | 0.03% | 114,833 | Common | SOLE |
| 03969T109 | ARCT | Arcturus Therapeutics Holdings Inc. | $2.6M | 0.03% | 151,329 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $2.3M | 0.02% | 1,557,630 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio Co. | $2.1M | 0.02% | 1,944,945 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA Pharma Inc. | $1.6M | 0.02% | 812,814 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $1.6M | 0.02% | 1,086,115 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $1.3M | 0.01% | 97,314 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $1.2M | 0.01% | 97,079 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics, Inc. | $920,856 | 0.01% | 20,400 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $805,435 | 0.01% | 797,460 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $486,256 | 0.01% | 322,024 | Common | SOLE |
| 004890109 | ACRV | Acrivon Therapeutics, Inc. | $318,368 | 0.00% | 52,885 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $212,527 | 0.00% | 45,027 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $147,437 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $17,833 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.